NovoCure (NASDAQ: NVCR) has faced a tough year, with its stock declining 35% since January, primarily due to a disappointing fourth-quarter update, despite broader market issues. However, there is potential for recovery, as Wall Street’s average price target for the stock is $32.57, suggesting a possible increase of nearly 70% from current levels. This raises the question of whether investors should share the optimism reflected in the analysts’ projections for NovoCure.
